Here's How Charles River Stock Is Placed Ahead of Q3 Earnings

Core Insights - Charles River Laboratories International, Inc. (CRL) is set to report its third-quarter 2025 results on November 5, with adjusted earnings per share (EPS) of $3.12 in the last quarter exceeding the Zacks Consensus Estimate by 24.80% [1] Q3 Estimates - The Zacks Consensus Estimate for CRL's revenues is $984.6 million, indicating a 2.5% decline from the previous year [2] - The Zacks Consensus Estimate for EPS is $2.32, reflecting a 10.4% year-over-year decrease [2] Estimate Revision Trend - Earnings estimates for CRL's third quarter have decreased by 1 cent in the past week [3] Factors Impacting Performance - Research Models and Services (RMS): Expected revenue growth of 6.5% in Q3 2025, driven by strong sales in research model services and favorable pricing, particularly in the GEMS and Insourcing Solutions businesses [4][5] - Discovery and Safety Assessment (DSA): Anticipated revenue decline of 7% due to budget pressures from biopharmaceutical clients and cash constraints faced by smaller biotech firms [6][8] - Manufacturing Solutions: Projected revenue drop of 0.6% in Q3 2025, influenced by geopolitical tensions and supply chain disruptions, although the Microbial Solutions business is expected to perform well [9][10] Earnings Whispers - CRL has an Earnings ESP of +0.61% and a Zacks Rank of 3, indicating a moderate chance of beating estimates [11]